Efficacy and Safety of Actovegin in Post-stroke Cognitive Impairment (PSCI)
Status:
Completed
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
The aim of this trial is to provide evidence that Actovegin has a symptomatic effect in
subjects with post stroke cognitive impairment (PSCI) during a six month treatment period
compared to subjects administered placebo. Subjects received IV infusions whilst in hospital,
and tablets once discharged. Subjects were followed up for a further six months after their
treatment had been stopped to explore if the cognitive symptoms of the subjects treated with
Actovegin showed sustained improvement. The trial also explored the possible prevention of
dementia with Actovegin in patients who had suffered a recent ischaemic stroke, as well as
the effect of Actovegin on other stroke outcomes. Safety information on Actovegin was
collected.